Get started
Keyword

eribulin

Description: Eribulin is an anticancer drug that disrupts microtubule dynamics and is used to treat certain advanced cancers, including breast cancer.
Wikidata ID: wiki/Q408717
OpenAlex ID: keywords/eribulin
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 · Mark Robson, Seock-Ah Im, et al. · New England Journal of Medicine · 3,287
PDF
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
2018 · Jennifer K. Litton, Hope S. Rugo, et al. · New England Journal of Medicine · 2,170
PDF
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 · Patrick Schöffski, Sant Chawla, et al. · The Lancet · 779
PDF
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
2019 · M.E. Robson, N. Tung, et al. · Annals of Oncology · 778
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
2023 · Hope S Rugo, Aditya Bardia, et al. · The Lancet · 491
PDF
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
2021 · Eric P Winer, Oleg Lipatov, et al. · The Lancet Oncology · 489
Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability
2009 · Jennifer A. Smith, Leslie Wilson, et al. · Biochemistry · 330
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
2012 · F. André, C.C. Zielinski · Annals of Oncology · 329
PDF
Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
2022 · Hope S. Rugo, Aditya Bardia, et al. · Journal of Clinical Oncology · 316
The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies
2019 · Lindsay Angus, Marcel Smid, et al. · Nature Genetics · 309
Update on taxane development: new analogs and new formulations
2012 · Katherine Tkaczuk, Jean Yared · Drug Design Development and Therapy · 252
PDF
Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development
2014 · David Newman, Gordon Cragg · Marine Drugs · 250
PDF
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
2007 · F A L M Eskens, C H Mom, et al. · British Journal of Cancer · 231
PDF
Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: Implications for chemotherapy-induced peripheral neuropathy
2013 · Nichole E. LaPointe, Gerardo Morfini, et al. · NeuroToxicology · 220
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies
2014 · Chris Twelves, Javier Cortes, et al. · Breast Cancer Research and Treatment · 217
PDF
Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
2008 · Tatiana Okouneva, Olga Azarenko, et al. · Molecular Cancer Therapeutics · 206
Chemotherapy for soft tissue sarcoma
2016 · Ravin Ratan, Shreyaskumar R. Patel · Cancer · 202
PDF
Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine
2017 · George D. Demetri, Patrick Schöffski, et al. · Journal of Clinical Oncology · 174
The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors
2017 · Allison S. Harney, George S. Karagiannis, et al. · Molecular Cancer Therapeutics · 161
Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells
2019 · Naotaka Hayasaka, Kohichi Takada, et al. · Scientific Reports · 155
PDF
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2020 · Sara M. Tolaney, Romualdo Barroso-Sousa, et al. · JAMA Oncology · 151
PDF
Enriching cancer pharmacology with drugs of marine origin
2019 · Paula C. Jimenez, Diego V. Wilke, et al. · British Journal of Pharmacology · 145
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
2018 · Sonia Pernas, Miguel Martin, et al. · The Lancet Oncology · 143
Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions
2010 · Murray J. Towle, Kathleen A. Salvato, et al. · Cancer Research · 139
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients.
2003 · Shazli N Malik, Lillian L Siu, et al. · PubMed · 129
Works count: 2,942
Citation count: 27,280
Year
Topic
Type